

Robert S Wallis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/551564/publications.pdf>

Version: 2024-02-01

105
papers

8,957
citations

41344

49
h-index

42399

92
g-index

107
all docs

107
docs citations

107
times ranked

8095
citing authors

#	ARTICLE	IF	CITATIONS
1	Granulomatous Infectious Diseases Associated with Tumor Necrosis Factor Antagonists. <i>Clinical Infectious Diseases</i> , 2004, 38, 1261-1265.	5.8	911
2	The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. <i>European Respiratory Journal</i> , 2010, 36, 1185-1206.	6.7	444
3	Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice. <i>Lancet</i> , The, 2010, 375, 1920-1937.	13.7	404
4	High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 39-49.	9.1	294
5	Advancing host-directed therapy for tuberculosis. <i>Nature Reviews Immunology</i> , 2015, 15, 255-263.	22.7	276
6	Tumour necrosis factor antagonists: structure, function, and tuberculosis risks. <i>Lancet Infectious Diseases</i> , The, 2008, 8, 601-611.	9.1	265
7	Host-directed therapies for infectious diseases: current status, recent progress, and future prospects. <i>Lancet Infectious Diseases</i> , The, 2016, 16, e47-e63.	9.1	265
8	Depressed T _H 1 Cell Interferon- γ Responses in Pulmonary Tuberculosis: Analysis of Underlying Mechanisms and Modulation with Therapy. <i>Journal of Infectious Diseases</i> , 1999, 180, 2069-2073.	4.0	256
9	Immunological mechanisms of human resistance to persistent <i>Mycobacterium tuberculosis</i> infection. <i>Nature Reviews Immunology</i> , 2018, 18, 575-589.	22.7	241
10	Tuberculosis—advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers. <i>Lancet Infectious Diseases</i> , The, 2016, 16, e34-e46.	9.1	223
11	A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis. <i>Nature Medicine</i> , 2018, 24, 1708-1715.	30.7	219
12	Granulomatous Infections Due to Tumor Necrosis Factor Blockade: Correction. <i>Clinical Infectious Diseases</i> , 2004, 39, 1254-1255.	5.8	215
13	Tuberculosis biomarkers discovery: developments, needs, and challenges. <i>Lancet Infectious Diseases</i> , The, 2013, 13, 362-372.	9.1	208
14	Tumor Necrosis Factor Antagonists: Different Kinetics and/or Mechanisms of Action May Explain Differences in the Risk for Developing Granulomatous Infection. <i>Seminars in Arthritis and Rheumatism</i> , 2006, 36, 159-167.	3.4	207
15	A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis. <i>Aids</i> , 2004, 18, 257-264.	2.2	202
16	Reactivation of Latent Granulomatous Infections by Infliximab. <i>Clinical Infectious Diseases</i> , 2005, 41, S194-S198.	5.8	178
17	Tumor Necrosis Factor Blockers: Differential Effects on Mycobacterial Immunity. <i>Journal of Infectious Diseases</i> , 2006, 194, 486-492.	4.0	169
18	Biomarkers for tuberculosis disease activity, cure, and relapse. <i>Lancet Infectious Diseases</i> , The, 2009, 9, 162-172.	9.1	164

#	ARTICLE	IF	CITATIONS
19	Therapeutic Use of Infliximab in Tuberculosis to Control Severe Paradoxical Reaction of the Brain and Lymph Nodes. <i>Clinical Infectious Diseases</i> , 2008, 47, e83-e85.	5.8	159
20	Human <i>Mycobacterium tuberculosis</i> -reactive CD4+ T-cell clones: heterogeneity in antigen recognition, cytokine production, and cytotoxicity for mononuclear phagocytes. <i>Infection and Immunity</i> , 1991, 59, 2737-2743.	2.2	143
21	Tumor necrosis factor and granuloma biology: Explaining the differential infection risk of etanercept and infliximab. <i>Seminars in Arthritis and Rheumatism</i> , 2005, 34, 34-38.	3.4	141
22	Sterilizing Activities of Novel Combinations Lacking First- and Second-Line Drugs in a Murine Model of Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 3114-3120.	3.2	138
23	Immunoadjuvant Prednisolone Therapy for HIV-Associated Tuberculosis: A Phase 2 Clinical Trial in Uganda. <i>Journal of Infectious Diseases</i> , 2005, 191, 856-865.	4.0	137
24	Mycobactericidal Activity of Sutezolid (PNU-100480) in Sputum (EBA) and Blood (WBA) of Patients with Pulmonary Tuberculosis. <i>PLoS ONE</i> , 2014, 9, e94462.	2.5	121
25	Drug Tolerance in <i>Mycobacterium tuberculosis</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 1999, 43, 2600-2606.	3.2	115
26	Biomarker-Assisted Dose Selection for Safety and Efficacy in Early Development of PNU-100480 for Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 567-574.	3.2	115
27	Whole Blood Bactericidal Activity during Treatment of Pulmonary Tuberculosis. <i>Journal of Infectious Diseases</i> , 2003, 187, 270-278.	4.0	113
28	Adalimumab Treatment of Life-Threatening Tuberculosis. <i>Clinical Infectious Diseases</i> , 2009, 48, 1429-1432.	5.8	113
29	Reconsidering Adjuvant Immunotherapy for Tuberculosis. <i>Clinical Infectious Diseases</i> , 2005, 41, 201-208.	5.8	111
30	Towards host-directed therapies for tuberculosis. <i>Nature Reviews Drug Discovery</i> , 2015, 14, 511-512.	46.4	110
31	Pharmacokinetics and Whole-Blood Bactericidal Activity against <i>Mycobacterium tuberculosis</i> of Single Doses of PNU-100480 in Healthy Volunteers. <i>Journal of Infectious Diseases</i> , 2010, 202, 745-751.	4.0	95
32	Dyscoordinate Expression of Tumor Necrosis Factor-alpha by Human Blood Monocytes and Alveolar Macrophages. <i>The American Review of Respiratory Disease</i> , 1989, 139, 1010-1016.	2.9	87
33	Inhibition of Mycobacterial Growth <i>In Vitro</i> following Primary but Not Secondary Vaccination with <i>Mycobacterium bovis</i> BCG. <i>Vaccine Journal</i> , 2013, 20, 1683-1689.	3.1	85
34	Cytokines and tuberculosis. <i>Journal of Leukocyte Biology</i> , 1994, 55, 676-681.	3.3	82
35	Infectious complications of tumor necrosis factor blockade. <i>Current Opinion in Infectious Diseases</i> , 2009, 22, 403-409.	3.1	78
36	Lifetime burden of disease due to incident tuberculosis: a global reappraisal including post-tuberculosis sequelae. <i>The Lancet Global Health</i> , 2021, 9, e1679-e1687.	6.3	74

#	ARTICLE	IF	CITATIONS
37	Host-directed immunotherapy of viral and bacterial infections: past, present and future. <i>Nature Reviews Immunology</i> , 2023, 23, 121-133.	22.7	71
38	Biomarkers for tuberculosis disease activity, cure, and relapse. <i>Lancet Infectious Diseases</i> , The, 2010, 10, 68-69.	9.1	64
39	Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial. <i>Lancet Respiratory Medicine</i> , the, 2021, 9, 897-908.	10.7	64
40	Rapid Evaluation in Whole Blood Culture of Regimens for XDR-TB Containing PNU-100480 (Sutezolid), TMC207, PA-824, SQ109, and Pyrazinamide. <i>PLoS ONE</i> , 2012, 7, e30479.	2.5	63
41	Enhanced Production of Recombinant <i>Mycobacterium tuberculosis</i> Antigens in <i>Escherichia coli</i> by Replacement of Low-Usage Codons. <i>Infection and Immunity</i> , 2000, 68, 233-238.	2.2	61
42	Biomarkers for tuberculosis disease status and diagnosis. <i>Current Opinion in Pulmonary Medicine</i> , 2009, 15, 181-187.	2.6	60
43	Month 2 Culture Status and Treatment Duration as Predictors of Tuberculosis Relapse Risk in a Meta-Regression Model. <i>PLoS ONE</i> , 2013, 8, e71116.	2.5	58
44	Bactericidal Activity in Whole Blood as a Potential Surrogate Marker of Immunity after Vaccination against Tuberculosis. <i>Vaccine Journal</i> , 2002, 9, 901-907.	3.1	57
45	Bactericidal activity of OPC-67683 against drug-tolerant <i>Mycobacterium tuberculosis</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 60, 994-998.	3.0	55
46	Induction of the Antigen 85 Complex of <i>Mycobacterium tuberculosis</i> in Sputum: A Determinant of Outcome in Pulmonary Tuberculosis Treatment. <i>Journal of Infectious Diseases</i> , 1998, 178, 1115-1121.	4.0	54
47	Mathematical modeling of the cause of tuberculosis during tumor necrosis factor blockade. <i>Arthritis and Rheumatism</i> , 2008, 58, 947-952.	6.7	54
48	Advances in Immunotherapy for Tuberculosis Treatment. <i>Clinics in Chest Medicine</i> , 2009, 30, 769-782.	2.1	54
49	Treatment of HIV-Related Inflammatory Cerebral Cryptococcoma with Adalimumab. <i>Clinical Infectious Diseases</i> , 2010, 50, e7-e10.	5.8	54
50	Reactivation of Latent Tuberculosis by TNF Blockade: The Role of Interferon γ . <i>Journal of Investigative Dermatology Symposium Proceedings</i> , 2007, 12, 16-21.	0.8	53
51	Safety and Immunogenicity of the Recombinant BCG Vaccine AERAS-422 in Healthy BCG-naïve Adults: A Randomized, Active-controlled, First-in-human Phase 1 Trial. <i>EBioMedicine</i> , 2016, 7, 278-286.	6.1	50
52	A Study of the Immunology, Virology, and Safety of Prednisone in HIV-1-Infected Subjects with CD4 Cell Counts of 200 to 700 mm ³ . <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2003, 32, 281-286.	2.1	46
53	Population Pharmacokinetic/Pharmacodynamic Analysis of the Bactericidal Activities of Sutezolid (PNU-100480) and Its Major Metabolite against Intracellular <i>Mycobacterium tuberculosis</i> in <i>Ex Vivo</i> Whole-Blood Cultures of Patients with Pulmonary Tuberculosis. <i>Antimicrobial Agents and Chemotherapy</i> . 2014. 58. 3306-3311.	3.2	46
54	Month 2 Culture Status and Treatment Duration as Predictors of Recurrence in Pulmonary Tuberculosis: Model Validation and Update. <i>PLoS ONE</i> , 2015, 10, e0125403.	2.5	46

#	ARTICLE	IF	CITATIONS
55	TB sequel: incidence, pathogenesis and risk factors of long-term medical and social sequelae of pulmonary TB – a study protocol. <i>BMC Pulmonary Medicine</i> , 2019, 19, 4.	2.0	45
56	SQ109 and PNU-100480 interact to kill <i>Mycobacterium tuberculosis</i> in vitro. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 1163-1166.	3.0	42
57	Here Today – Gone Tomorrow: The Case for Transient Acute Tuberculosis Infection. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 174, 734-735.	5.6	39
58	Glutathione and growth inhibition of <i>Mycobacterium tuberculosis</i> in healthy and HIV infected subjects. <i>AIDS Research and Therapy</i> , 2006, 3, 5.	1.7	39
59	Duration of Fever during Treatment of Infective Endocarditis. <i>Medicine (United States)</i> , 1992, 71, 52.	1.0	36
60	Biologics and Infections: Lessons from Tumor Necrosis Factor Blocking Agents. <i>Infectious Disease Clinics of North America</i> , 2011, 25, 895-910.	5.1	36
61	Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine. <i>European Respiratory Journal</i> , 2016, 48, 1526-1527.	6.7	36
62	Inhibition of Isoniazid-Induced Expression of <i>Mycobacterium tuberculosis</i> Antigen 85 in Sputum: Potential Surrogate Marker in Tuberculosis Chemotherapy Trials. <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 1302-1304.	3.2	32
63	Vitamin D as Adjunctive Host-Directed Therapy in Tuberculosis: A Systematic Review. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw151.	0.9	31
64	Mathematical Models of Tuberculosis Reactivation and Relapse. <i>Frontiers in Microbiology</i> , 2016, 7, 669.	3.5	29
65	High Incidence of Kaposi's Sarcoma – Associated Herpesvirus and Epstein – Barr Virus in Tumor Lesions and Peripheral Blood Mononuclear Cells from Patients with Kaposi's Sarcoma in Uganda. <i>Journal of Infectious Diseases</i> , 1997, 175, 947-950.	4.0	27
66	Sustainable Tuberculosis Drug Development. <i>Clinical Infectious Diseases</i> , 2013, 56, 106-113.	5.8	27
67	T cell activation by mycobacterial antigens in inflammatory synovitis. <i>Cellular Immunology</i> , 1991, 133, 95-108.	3.0	23
68	Lack of Activity of Orally Administered Clofazimine against Intracellular <i>Mycobacterium tuberculosis</i> in Whole-Blood Culture. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 3133-3135.	3.2	23
69	Survival and Replication of Clinical <i>Mycobacterium tuberculosis</i> Isolates in the Context of Human Innate Immunity. <i>Infection and Immunity</i> , 2005, 73, 2595-2601.	2.2	23
70	Biomarkers of Disease Activity, Cure, and Relapse in Tuberculosis. <i>Clinics in Chest Medicine</i> , 2009, 30, 783-796.	2.1	20
71	Persistence, Not Resistance, Is the Cause of Loss of Isoniazid Effect. <i>Journal of Infectious Diseases</i> , 2007, 195, 1870-1871.	4.0	17
72	Activity of nitazoxanide and tizoxanide against <i>Mycobacterium tuberculosis</i> in vitro and in whole blood culture. <i>Tuberculosis</i> , 2016, 98, 92-96.	1.9	17

#	ARTICLE	IF	CITATIONS
73	Pan-tuberculosis regimens: an argument for. <i>Lancet Respiratory Medicine</i> , 2018, 6, 239-240.	10.7	16
74	Probit: a computer program analysis. <i>Journal of Immunological Methods</i> , 1991, 145, 267-268.	1.4	15
75	Clinical, Microbiological, and Immunological Characteristics in HIV-Infected Subjects at Risk for Disseminated <i>Mycobacterium avium</i> Complex Disease: An AACTG Study. <i>AIDS Research and Human Retroviruses</i> , 2005, 21, 689-695.	1.1	15
76	Corticosteroid Effects on Sputum Culture in Pulmonary Tuberculosis: A Meta-Regression Analysis. <i>Open Forum Infectious Diseases</i> , 2014, 1, ofu020.	0.9	15
77	Strain specificity of antimycobacterial immunity in whole blood culture after cure of tuberculosis. <i>Tuberculosis</i> , 2009, 89, 221-224.	1.9	14
78	Application of a whole blood mycobacterial growth inhibition assay to study immunity against <i>Mycobacterium tuberculosis</i> in a high tuberculosis burden population. <i>PLoS ONE</i> , 2017, 12, e0184563.	2.5	14
79	Pulmonary Infectious Complications of Tumor Necrosis Factor Blockade. <i>Infectious Disease Clinics of North America</i> , 2010, 24, 681-692.	5.1	13
80	Protein binding of rifampicin is not saturated when using high-dose rifampicin. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 986-990.	3.0	13
81	Measurement of Induced Cytokines in AIDS Clinical Trials Using Whole Blood: A Preliminary Report. <i>Vaccine Journal</i> , 1998, 5, 556-560.	2.6	13
82	Application of a Stochastic Modeling to Assess the Evolution of Tuberculous and Non-Tuberculous Mycobacterial Infection in Patients Treated with Tumor Necrosis Factor Inhibitors. <i>PLoS ONE</i> , 2013, 8, e55017.	2.5	13
83	Adult tuberculosis in the 21st century: pathogenesis, clinical features, and management. <i>Current Opinion in Pulmonary Medicine</i> , 2001, 7, 124-132.	2.6	11
84	Early Biomarkers and Regulatory Innovation in Multidrug-Resistant Tuberculosis. <i>Clinical Infectious Diseases</i> , 2015, 61, S160-S163.	5.8	10
85	Surrogate markers to assess new therapies for drug-resistant tuberculosis. <i>Expert Review of Anti-Infective Therapy</i> , 2007, 5, 163-168.	4.4	9
86	Mycobacterial Disease Attributable to Tumor Necrosis Factor Inhibitor Blockers. <i>Clinical Infectious Diseases</i> , 2008, 47, 1603-1605.	5.8	8
87	Lack of a Therapeutic Role for Interferon γ in Patients With Tuberculosis. <i>Journal of Infectious Diseases</i> , 2014, 209, 627-628.	4.0	8
88	TB Chemotherapy. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2004, 169, 771-772.	5.6	8
89	Biomarkers for tuberculosis disease activity, cure, and relapse – Authors' reply. <i>Lancet Infectious Diseases</i> , 2010, 10, 70-71.	9.1	7
90	Early bactericidal activity of new drug regimens for tuberculosis. <i>Lancet</i> , 2013, 381, 111-112.	13.7	7

#	ARTICLE	IF	CITATIONS
91	Mycobactericidal activity of bedaquiline plus rifabutin or rifampin in ex vivo whole blood cultures of healthy volunteers: A randomized controlled trial. PLoS ONE, 2018, 13, e0196756.	2.5	6
92	Acquired rifamycin resistance: pharmacology and biology. Expert Review of Anti-Infective Therapy, 2008, 6, 223-230.	4.4	5
93	Sputum culture conversion as a tuberculosis biomarker: a glass half empty or half full?. Lancet Respiratory Medicine, the, 2015, 3, 174-175.	10.7	5
94	Anti-tuberculosis treatment and infliximab. Respiratory Medicine, 2005, 99, 1620-1622.	2.9	4
95	Lung and blood early biomarkers for host-directed tuberculosis therapies: Secondary outcome measures from a randomized controlled trial. PLoS ONE, 2022, 17, e0252097.	2.5	4
96	Can Studies of the Early Bactericidal Activity of Rifapentine Tell Us How to Prevent Acquired Rifamycin-Resistant Relapse?. American Journal of Respiratory and Critical Care Medicine, 2005, 172, 4-5.	5.6	2
97	Tumor necrosis factor- α inhibitors and granulomatous infectious. Drug Discovery Today Disease Mechanisms, 2006, 3, 295-300.	0.8	2
98	Corticosteroids and HIV infection: a review of experience. Current Opinion in HIV and AIDS, 2007, 2, 213-218.	3.8	2
99	Chapter 22: Assessment of Whole-Blood Bactericidal Activity in the Evaluation of New Antituberculosis Drugs. Progress in Respiratory Research, 2011, , 220-226.	0.1	2
100	Sputum culture conversion in new TB regimens. Lancet Respiratory Medicine, the, 2015, 3, e18-e19.	10.7	2
101	Mycobacterial Growth Inhibition Assay (MGIA) as a Host Directed Diagnostic Tool for the Evaluation of the Immune Response in Subjects Living With Type 2 Diabetes Mellitus. Frontiers in Cellular and Infection Microbiology, 2021, 11, 640707.	3.9	2
102	Quantitative Systems Pharmacology Modeling Framework of Autophagy in Tuberculosis: Application to Adjunctive Metformin Host-Directed Therapy. Antimicrobial Agents and Chemotherapy, 2022, 66, .	3.2	2
103	Structural-Functional Relationships of TNF-Alpha Antagonists: Next Steps. Journal of Investigative Dermatology Symposium Proceedings, 2007, 12, 46-47.	0.8	0
104	Significance of Early Secreted Antigenic Target 6-Specific T Cell Depletion after HIV-1 Infection. Journal of Infectious Diseases, 2009, 200, 158-158.	4.0	0
105	Clinical Trials of TB-HDT Candidates. , 2021, , 285-293.		0